These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27553679)

  • 1. High Frequency of Bone Marrow Involvement in Intravascular Large B-Cell Lymphoma.
    Wang J; Ding W; Gao L; Yao W; Chen M; Zhao S; Liu W; Zhang W
    Int J Surg Pathol; 2017 Apr; 25(2):118-126. PubMed ID: 27553679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
    Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
    Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase.
    Zou D; Yi S; Cui R; Liu W; Li C; Zhong S; Yu Z; Li Z; Lv R; Ru K; Wang H; An G; Xu Y; Qiu L
    BMC Med Genet; 2017 Feb; 18(1):16. PubMed ID: 28209136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV-positive intravascular large B-cell lymphoma of the liver: a case report and literature review.
    Li Q; Li J; Yang K; Peng Y; Xiang Y; Sun S; Zeng J; Zhang X; Wang J
    Diagn Pathol; 2020 Jun; 15(1):72. PubMed ID: 32513269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary adrenal diffuse large B cell lymphoma: a clinicopathological and molecular study from China.
    Zhang J; Sun J; Feng J; Luo Y; Ling Q; Wu S; Zeng X; Liang Z
    Virchows Arch; 2018 Jul; 473(1):95-103. PubMed ID: 29802470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Concurrent Expression of C-MYC and BCL2 in Intravascular Large B-Cell Lymphoma: A 10-Year Retrospective Study.
    Boonsakan P; Iamsumang W; Chantrathammachart P; Chayavichitsilp P; Suchonwanit P; Rutnin S
    Biomed Res Int; 2020; 2020():1350820. PubMed ID: 32566654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.
    Yegappan S; Coupland R; Arber DA; Wang N; Miocinovic R; Tubbs RR; Hsi ED
    Mod Pathol; 2001 Nov; 14(11):1147-56. PubMed ID: 11706077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
    Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.
    Murase T; Yamaguchi M; Suzuki R; Okamoto M; Sato Y; Tamaru J; Kojima M; Miura I; Mori N; Yoshino T; Nakamura S
    Blood; 2007 Jan; 109(2):478-85. PubMed ID: 16985183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
    Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature.
    Bhagavathi S; Micale MA; Les K; Wilson JD; Wiggins ML; Fu K
    Am J Surg Pathol; 2009 Oct; 33(10):1463-9. PubMed ID: 19675454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
    Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
    Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].
    Shen X; Zhou LT; Li AQ; Yi HM; Ouyang BS; Xu HM; Xie JL; Gu YJ; Zhang L; Dong L
    Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):120-125. PubMed ID: 35152630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.